|
|
||||||||
Ann Thorac Surg 2001;71:S190
© 2001 The Society of Thoracic Surgeons
a Heart Transplantation and Circulatory Assist Device Program, Washington Hospital Center, Washington, DC, USA
b Kriton Medical, Sacramento, California, USA
Address reprint requests to Dr Boyce, 106 Irving St NW, Suite 316, Washington, DC 20010
e-mail: swb1{at}mhg.edu
Presented at the Fifth International Conference on Circulatory Support Devices for Severe Cardiac Failure, New York, NY, Sept 1517, 2000.
First-generation, volume-displacement blood pumps unload the left ventricle and assume a substantial portion of its pumping function. However, surgeons have not widely adopted these devices because the pumps are constrained by their size, weight, infection rate, thrombogenic potential, and reliability issues [1]. Smaller, second-generation axial flow blood pumps now emerging typically feature contacting bearings that may wear or become thrombogenic.
The Kriton Medical implantable device is a third-generation, centrifugal flow blood pump. The pumps displaced volume, including the inflow tube, is 48 mL. Magnetic and hydrodynamic forces suspend the pumps rotor and prevent it from contacting the housing; because these parts do not touch each other, the device is wearless.
Within the most recent 10 months, surgeons have implanted Kriton Medical blood pumps in 13 sheep for a combined 341 implant days. None of the animals received anticoagulation beyond the immediate perioperative period. These studies demonstrated reliable pump function, pulsatile flow, 15 L/min maximum flow, and insignificant hemolysis (plasma free hemoglobin of approximately 6 mg/dL). Most recently, one 60-day trial and two 90-day trials were terminated electively, and there was no evidence of macroscopic thrombi in any of the pumps.
Animal and laboratory evaluations indicate that the Kriton Medical third-generation centrifugal flow blood pump is anatomically compatible, wearless, highly reliable, and nonthrombogenic. The device represents a potential long-term congestive heart failure solution.
Footnotes
Dr Boyce is a Medical Consultant for Kriton Medical, Inc, while Ms Crevensten is a Project Engineer and Dr Fine is CEO and President of the company.
References
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |